Hospital

An overview of current theses and research surrounding the pathogenesis, presentation, and treatment of COVID-19 in children.

The opportunity to provide non-invasive colorectal cancer screening and education to patients is undoubtedly a role that pharmacists can fill.

The protein, called suPAR, has long been known to be a biomarker for poor outcomes and disease progression in both kidney disease and cardiovascular disease.

Big pharma companies have become more measured in their risk taking, with mergers and acquisitions gradually giving way to joint ventures and partnerships.

This week's episode features Tom Frieden, MPH, MD, who discusses his background and influence on public health and national policy.

Judy Neville speaks with pharmacy technicians about the impact of pharmacy technician as vaccinators.

A study showed that the risk of developing venous thromboembolism is worse for perimenopausal women with diabetes.

Children who experienced COVID-19-induced multisystem inflammatory syndrome did not experience severe adverse reactions following COVID-19 vaccination.

The FDA granted fidanacogene elaparvovec breakthrough, regenerative medicines advance therapy, and orphan drug designations.

The dual-action cell therapy is designed to eliminate established tumors, train the immune system to eradicate a primary tumor, and prevent recurrence.

Greater prevalence of hand eczema among health care professionals working in COVID-19 units linked to increased hand sanitation habits.

The changes will almost certainly widen access for patients seeking medicated abortions in states without legal obstacles.

Biomarkers are commonly used by physicians to assist in the earlier diagnosis of some of the most common fungal diseases.

Embracing these new standards is the right thing to do for patient safety.

Some US pharmacies are experiencing medication shortages as a result of COVID-19, influenza, and respiratory syncytial virus cases.

Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.

The subcutaneous formulation could enhance treatment options by providing high consistency in drug exposure and a convenient administration method.

In addition to the physical symptoms of long COVID, patients have reported vocal, verbal, and cognitive issues that disrupt their ability to communicate.

Patient-centric models of medication delivery that provide cost, transparency, convenience, and accessibility solutions are vital for patients to successfully navigate the current health care system.

From newsworthy moments to groundbreaking research, these were the most-read articles on Pharmacy Times in 2022.

Pain management and the opioid epidemic dominated the top health system articles in 2022.

The National Institute of Health’s grant funds a phase 2 clinical trial of doxycycline in a large group of individuals with the 2 conditions who are smokers or used to smoke.

In 10 states, the data showed more than 26% of women had limited accessibility to mammography, primarily in the Rocky Mountains and the South.

Participants who survived Hodgkin lymphoma as children showed signs of being biologically older than their peers, with a heightened risk of cognitive problems.

The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.

Jawad Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of Pharmacy Services at the Hospital for Special Surgery, discusses how pharmacists can treat postoperative nausea and vomiting.

Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.

From newsworthy moments to groundbreaking research, these are the most popular articles in the zoster space, published on Pharmacy Times® during 2022.

Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen.

The FDA approved lenacapavir, which is the first approval of a drug in a new class of antiretrovirals for the treatment of HIV-1 called capsid inhibitors.